Source-backed half-life profile
Cocaine half-life calculator
Cocaine is a short parent-drug curve with a long list of ways people can overread it. The page deliberately separates the parent compound from metabolite and risk questions.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The model declines quickly, but that does not make cardiovascular effects, toxicity, or testing interpretation simple.
Source angle
Look for whether a source is discussing cocaine itself, a formulation or route, or metabolite findings such as benzoylecgonine.
Do not use it for
Do not use this page for testing predictions, impairment decisions, or safety timing.
Best next step
Compare cocaine with crack cocaine to see why route context belongs beside the half-life number.
Cocaine: evidence and interpretation notes
The one-hour curve follows parent cocaine
Inaba’s human pharmacokinetics review reports short elimination half-lives estimated from serial plasma measurements: approximately 0.5 to 1.1 hours after intravenous administration and 0.9 to 1.5 hours after nasal or oral administration. HalfLifeDB uses one hour as a readable center point across those reported parent-drug values.
That choice is deliberately specific. The line does not represent benzoylecgonine, ecgonine methyl ester, norcocaine, or a laboratory’s collection threshold. Cocaine is transformed through more than one pathway, and downstream analytes can have timelines that differ from the rapidly falling parent compound.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| Inaba human pharmacokinetics review | Route-specific plasma ranges and biotransformation context | The literature summarized is older and includes differing routes |
| Bravo analytical review | Modern overview of chemistry, metabolites, and measurement | Analytical persistence is not parent-drug half-life |
| Scheidweiler oral-fluid study | Controlled measurements of cocaine and metabolites in another matrix | Oral-fluid findings should not be substituted for plasma curves |
| PubChem identity record | Compound identity | It does not support a detection or impairment timeline |
Route changes the front of the curve
The Inaba review reports different ranges by route, but route also changes absorption and peak timing. A single elimination plot begins after an abstract 100% starting point and therefore hides much of that early route-dependent behavior. It cannot recreate the rise in concentration, distribution, or actual peak reached in a study participant.
The Scheidweiler study makes another distinction visible: a measured matrix matters. Plasma, oral fluid, urine, and other specimens do not provide interchangeable timelines, particularly once metabolites and assay thresholds enter the question.
A steep line does not imply a short risk window
At five one-hour half-lives, the simplified parent curve is near 3%. That observation does not establish that cardiovascular effects, impairment, toxicity, or detectability have ended. It also does not account for repeated exposure, delayed absorption, co-exposures, individual enzyme activity, or clinical complications.
The page supports one narrow lesson: parent cocaine has a short reported plasma half-life, while many practical questions associated with cocaine are not parent-half-life questions. Those require clinical, toxicological, or laboratory context rather than extrapolation from this curve.
Reading this curve
HalfLifeDB uses 1 h as a representative input for Cocaine. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
Cocaine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 1.56% | Low modeled remainder, not a clearance guarantee |
| 12 h | 0.02% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.00% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Cocaine within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
Pharmacokinetics at a glance
| Representative half-life | 1 h |
|---|---|
| Reported range | 30 min to 1.5 h |
| Curve type | Normalized, first-order decline |
Selection note: A human pharmacokinetics review reports plasma elimination half-lives of 0.5 to 1.1 hours after IV administration and 0.9 to 1.5 hours after nasal or oral administration.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Research abstract Inaba T. Cocaine pharmacokinetics and biotransformation in humans (1989).Human review reporting route-dependent parent-cocaine half-lives and describing major biotransformation pathways.
- Full-text research Bravo RR et al. Cocaine: an updated overview on chemistry, detection and analysis (2022).Full-text review used for analytical and metabolite context, not as a personalized detection-window source.
- Full-text research Scheidweiler KB et al. Pharmacokinetics of cocaine and metabolites in human oral fluid (2010).Controlled human study illustrating that oral-fluid parent-drug and metabolite measurements answer different questions.
- Identity record PubChem Compound Summary: Cocaine.Compound identity record; background only.
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and profile review log before using the model for comparison.